Revolutionizing Aortic Regurgitation Care: egnite and JenaValve Announce Strategic Partnership
egnite, Inc., a leading digital health company for cardiovascular care, and JenaValve Technology, Inc., a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, have joined forces in a strategic partnership aimed at shedding light on the care paradigm and associated outcomes of patients with aortic regurgitation (AR). Leveraging egnite’s industry-leading database, this partnership seeks to quantify prevalence and treatment patterns, with estimates suggesting that over 500,000 patients in the United States may be diagnosed with moderate or severe AR.
“Our collaboration, which combines cutting-edge analytics and JenaValve’s innovative transcatheter therapies, aims to drive urgent change, provide improved treatment options, and ultimately save lives. These findings also offer valuable insights for healthcare providers and policymakers, fostering further attention toward enhancing outcomes for patients suffering from AR,” says Duane Pinto, MD, CMO of JenaValve.
Dr. Nicholas S. Amoroso, an interventional cardiologist, recently presented the first study resulting from this partnership at TVT: The Structural Heart Summit. The study, based on over 1 million patients from 25 leading cardiovascular programs across the United States, utilized egnite’s database to examine two-year treatment rates and outcomes for patients with AR.
Key findings from the study indicate that despite high two-year mortality rates and guideline indications for treatment, patients with severe AR received low rates of specialist evaluations and treatment with aortic valve replacement. The study also suggests that patients diagnosed with moderate or severe AR and severe left ventricular dilation exhibited similar mortality rates, underscoring the potential benefits of earlier assessment by the Heart Team.
Related Post :
- The impact of cross-cultural partnerships on business success
- Leveraging partnerships for talent acquisition and development
- The Importance of Communication in Partnerships and Alliances
“This groundbreaking artificial intelligence-driven study provides critical insights into care patterns for patients with moderate or greater AR in the community,” says Dr. Nicholas S. Amoroso, Assistant Professor at the Medical University of South Carolina. “The urgency for digital technologies to identify AR patients earlier and novel therapies to improve outcomes for this vulnerable patient population has never been greater.”
JenaValve Technology, Inc. is a medical device company focused on developing innovative transcatheter heart valve solutions for the treatment of patients with heart valve disease. Their Trilogy® Heart Valve System, a transcatheter aortic valve replacement (TAVR) system, is designed to treat patients with symptomatic, severe aortic regurgitation (ssAR) and symptomatic, severe aortic stenosis (ssAS) in high surgical risk patients. JenaValve has received Breakthrough Device Designation from the FDA for its pivotal trial in the U.S., aiming to obtain approval for the Trilogy System for the treatment of ssAR.
egnite, Inc. is a visionary digital health company dedicated to advancing society’s health through innovative cardiovascular solutions. Using AI-driven algorithms and big data, egnite produces business intelligence for healthcare, transforming care delivery for cardiovascular patients. By partnering with leading hospitals and life sciences organizations, egnite leverages data to elevate critical decisions in care.
The strategic partnership between egnite and JenaValve represents a significant step forward in addressing the challenges and improving the outcomes for patients with aortic regurgitation. By leveraging cutting-edge technologies and collaborative efforts, the potential for transformative change in the field of cardiovascular care is within reach.
For more information about JenaValve, visit www.jenavalve.com, and for egnite, visit www.egnitehealth.com.
Note: This press release contains certain statements that are forward-looking and involve risks and uncertainties. Please refer to the company’s SEC filings for more information on the risks and uncertainties that could cause actual results to differ materially from current expectations.
